|
|
|
|
|
|
|
|
126th MAINE LEGISLATURE |
|
|
LD 1600 |
|
LR 2402(03) |
|
|
|
An Act To Require
Health Insurers To Provide Coverage for Human Leukocyte Antigen Testing To
Establish Bone Marrow Donor Transplantation Suitability |
|
Fiscal Note for
Bill as Amended by Committee Amendment " " |
|
Committee: Insurance and Financial Services |
|
Fiscal Note Required: Yes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Note |
|
|
|
|
|
|
|
Potential future biennium cost increase - General Fund |
|
|
|
|
|
|
|
Fiscal Detail
and Notes |
|
|
|
|
|
|
Any additional
costs to the State Employee Health Insurance Program are expected to be minor
and can be absorbed within existing budgeted resources. The Patient Protection and Affordable Care
Act (ACA) requires States to defray the cost of mandated benefits not
included in the ACA's Essential Health Benefits. The Bureau of Insurance's report on LD 1600
to the Joint Standing Committee on Insurance and Financial Services estimated
the cost of increased coverage due to LD 1600 to be approximately $48,000 per
year. The specifics of this required
State payment under the ACA to defray the costs of this mandate (i.e., how
much, what program(s) and when) cannot be determined at this time. |
|
|
|
|
|
|
|